We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Summary Judgment Denial Clears Path For Abilify Trials

Law360 (March 16, 2018, 10:11 PM EDT) -- A Florida federal judge late Thursday released a redacted version of an order denying a bid for summary judgment from Otsuka Pharmaceutical and Bristol-Meyers Squibb in multidistrict litigation over alleged side effects of the anti-psychotic drug Abilify, paving the way for trials in consumers' cases this summer.

U.S. District Judge M. Casey Rodgers based her decision, which she originally issued the under seal to the parties on Jan. 22, on her determination that the consumers have shown their general causation evidence is sound and reliable and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.